April 1, 2011 - Three Clinical Studies at the American College of Cardiology Examine the Presage® ST2 Assay Across Clinical Presentations and Progression to Advanced Cardiovascular Disease - A novel cardiac biomarker, ST2, will be highlighted in three presentations at the American College of Cardiology (ACC) in New Orleans this week. These studies and others have demonstrated that a patient's ST2 level can help a physician better predict prognosis, change in cardiac status, and development of cardiovascular complications such as heart failure, at critical clinical decision points, including at initial presentation with chest pain, after recovery from myocardial infarction, and in the cardiac intensive care unit."We continue to find that ST2 is a valuable prognostic tool in assessing patients across various stages of cardiovascular disease," said Dr. James L. Januzzi, the Director of the Cardiac Intensive Care Unit at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. "In our recent study in Advanced Stage Heart Failure Patients, we concluded that measurement of ST2 may help us determine appropriate courses of action in these late-stage patients."...
[...]
..."We are pleased to see the research community continue to generate strong evidence that ST2 predicts outcomes for cardiovascular patients," said James Snider, President of Critical Diagnostics. "The studies presented here show that ST2 can be a valuable tool for clinicians across the spectrum of heart failure: from predicting onset to predicting outcomes in late-stage patients. These clinical data continue to build evidence that ST2 may help aid physicians in clinical decision-making."... Critical Diagnostics' Press Release -
